The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
AKERO THERAPEUTICS INC | COM | 00973Y108 | 20,310 | 596,483 | SH | SOLE | 596,483 | 0 | 0 | ||
ALX ONCOLOGY HLDGS INC | COM | 00166B105 | 92,828 | 9,699,925 | SH | SOLE | 9,699,925 | 0 | 0 | ||
CINCOR PHARMA INC | COM | 17240Y109 | 61,119 | 1,862,256 | SH | SOLE | 1,862,256 | 0 | 0 | ||
ELEVATION ONCOLOGY INC | COM | 28623U101 | 2,109 | 1,866,339 | SH | SOLE | 1,866,339 | 0 | 0 | ||
HARMONY BIOSCIENCES HLDGS IN | COM | 413197104 | 49,856 | 1,125,673 | SH | SOLE | 1,125,673 | 0 | 0 | ||
IMPEL PHARMACEUTICALS INC | COM | 45258K109 | 13,440 | 2,759,791 | SH | SOLE | 2,759,791 | 0 | 0 | ||
PHARVARIS N V | COM | N69605108 | 17,616 | 2,296,710 | SH | SOLE | 2,296,710 | 0 | 0 | ||
VENTYX BIOSCIENCES INC | COM | 92332V107 | 174,953 | 5,011,536 | SH | SOLE | 5,011,536 | 0 | 0 |